The share price of Israeli ophthalmology investment firm BioLight Life Sciences (TASE: BOLT) rose 2% today after Israeli glaucoma treatment company Belkin Vision, quanto a which it holds a 4% stake, announced that it had completed its restare di sale to Swiss-American ophthalmology company Alcon (SWX: ALC).
RELATED ARTICLES
BioLight reported the deal quanto a May and since then its share price has risen 40% and it currently has a market cap of NIS 22 million.
Alcon is acquiring Belkin Vision, which has developed laser-based technology for glaucoma treatment for up to $466 million, including an immediate payment of $81 million and a further $385 million quanto a milestone payments according to the product’s success the market.
BioLight will receive NIS 8.9 million cash immediately and payments of up to $10.8 million if Belkin Vision achieves all its milestones – quanto a other words an amount significantly higher than BioLight’s overall value. Prior to the announcement of Belkin Vision’s acquisition, Biolight had booked the value of its stake at just NIS 3.6 million.
US marketing approval
Last December, Belkin Vision received FDA marketing approval quanto a the US for its laser-based device for treating glaucoma. The company was founded quanto a 2013 as Belkin Laser to develop a non-contact laser treatment that is more effective and accessible quanto a the treatment of glaucoma. Per mezzo di February 2024 Belkin Vision raised $12.3 million, bringing the total amount raised by the company to $40 million. The company has also received a $17.5 million grant from the EU.
The company was founded by ophthalmologist Prof. Michael Belkin as part of Sheba Medical Center’s ARC project, together with CEO Daria Lemann-Blumenthal.
Alcon is expected to promote the use of Belkin Vision’s product as a first line treatment for glaucoma. Alcon is a leading international corporation quanto a the field of ophthalmology, and quanto a the field of glaucoma it markets eye care and implants, and now it will also add a laser product. The product has been approved for marketing quanto a Europe and the US, but to date has not been marketed quanto a the US.
Published by Globes, Israel business news – en.globes.co.il – July 3, 2024.
© of Globes Publisher Itonut (1983) Ltd., 2024.
